Promising Results of CNM-Au8 in MS Patients Presented at ECTRIMS 2025 Congress
Update: 2025-09-25
Description
Clene Inc. showcased encouraging outcomes from the REPAIR-MS trial at ECTRIMS 2025 Congress, demonstrating that CNM-Au8 enhanced brain NAD+/NADH ratios in MS patients, impacting energy capacity. The treatment correlated with changes in brain NAD+ and NADH fractions, influencing disability and cognitive function. CNM-Au8 exhibited good tolerability and potential in slowing MS progression by addressing bioenergetic failure, positioning it as a hopeful therapy under investigation by Clene Inc., a biopharmaceutical company specializing in neurodegenerative diseases.
Comments
In Channel